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A B S T R A C T
In the last ten years, several risk factors that increase the
risk of venous thrombosis have been discovered. Venous
thrombosis is a multicausal disease in which several risk
factors, both genetic and acquired, have to occur simul-
taneously to cause thrombosis. This means that most
individuals with single thrombophilia are asymptomatic.
Although testing thrombosis patients and their relatives
for thrombophilia factors seems important for tailoring
the duration of (prophylactic) anticoagulant therapy or
estimating the risk of recurrence of thrombosis, current
data do not support screening for thrombophilia. The risk
of recurrences or the duration of anticoagulant therapy
are generally not altered by thrombophilia. Future
research should focus on identifying clusters of thrombosis
risk factors to better estimate the individual risk of
thromboembolic events.
I N T R O D U C T I O N
Before 1993, an inherited risk factor was detectable in only
10% of symptomatic patients with venous thrombosis. In
the last ten years, the knowledge of risk factors for venous
thrombosis has increased significantly. With the discovery
of several inherited coagulation abnormalities associated
with an increased tendency for venous thrombosis, such
as factor V Leiden and the prothrombin 20210A mutation,
many patients with a first episode of venous thrombosis
have a detectable disorder.
Rudolph Virchow stated that the development of thrombosis
was the result of changes in blood composition (hyper-
coagulability), reduced blood flow, or changes in the 
vessel wall.1 Disturbance of this balance favours fibrin
formation and may ultimately lead to the formation of
occlusive thrombi. Examples of this pathophysiological
phenomenon are trauma, immobilisation, pregnancy,
surgery, malignancy and infection. These are acquired
risk factors for venous thrombosis that may cause tissue
damage, stasis of the blood or changes in blood composition.
Both family studies and case-control studies led to im-
portant discoveries of heritable causes of thrombosis. 
The Leiden Thrombophilia Study (LETS), a population-
based large case-control study, assessed the importance of
various risk factors for thrombosis, which in most cases
had been identified by family studies.2 Table 1 summarises
the main results of the LETS. The thrombophilia factors
can roughly be divided in two groups: deficiencies in the
anticoagulant proteins antithrombin, protein C, and
protein S are loss of function mutations and are rare in
the general population. The prothrombotic abnormalities
have a gain of function through subtle changes in the
regulation of the gene activity. Factor V Leiden is rela-
tively resistant to inactivation by activated protein C
(APC) and the prothrombin mutation leads to increased
prothrombin levels. High levels of procoagulant factors,
such as factor VIII, IX and XI, lead to prolonged formation
of fibrin as a result of excessive generation of thrombin.
Finally, high thrombin-activatable fibrinolysis inhibitor
(TAFI) levels result in prolonged down-regulation of
fibrinolysis. Since no mutations have been found that
elevate these coagulation factors, we do not know whether
a gain or loss of function is responsible.
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Interaction
Venous thrombosis like many other diseases is multicausal.
The discovery of common risk factors was a prerequisite
for the study of interaction and made it clear that risk
factors for thrombosis result from genetic differences or
differences brought about by the environment or even
behaviour. Plasma levels of proteins can, for instance, be
determined by polymorphisms in the functional allele and
by age or hormones. A good example of this complicated
regulation is factor VIII. ABO blood group is an important
genetic determinant of plasma factor VIII levels.3 Von
Willebrand factor is the carrier protein of factor VIII in
plasma and also determines the factor VIII level.4 If 
both blood group and von Willebrand factor are taken
into account, a clear familial clustering remains, suggesting
a third set of genes that regulate factor VIII levels.5 Apart
from the genetic causes, factor VIII is also influenced by
environmental factors such as acute phase reactions and
age. It is clear that not only is thrombosis a multicausal
disease, but that the level of coagulation factors also reflects
a mixture of genetic and environmental determinants.6,7
The mean age at first thrombosis for patients from
thrombophilic families is much younger than for con-
secutive patients with thrombosis.8 This phenomenon is
probably due to interaction of several genetic defects. In
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Table 1
Results from the Leiden Thrombophilia Study
RISK FACTOR PREVALENCE IN PREVALENCE IN OR 95% CI
PATIENTS (%) CONTROLS (%)
ANTICOAGULANT PROTEINS
Protein C <0.67 U/ml 4.6 0.8 3.8 1.7-7.0
Protein S <0.67 U/ml 1.1 1.3 0.8 0.2-3.0
Antithrombin <0.80 U/ml 1.1 0.2 5.0 0.7-34
PROTHROMBOTIC MUTATIONS
Factor V Leiden mutation 19 3 7.9 4.4-14
Prothrombin 20210A mutation 6.2 2.3 2.8 1.4-5.6
ELEVATED LEVELS OF PROCOAGULANT FACTORS
Factor VIII >150 IU/dl 25 11 6.2 3.4-11
Factor IX >129 U/dl 20 10 2.5 1.6-3.9
Factor XI >120.8% 19 10 2.2 1.5-3.2
FIBRINOLYTIC FACTORS
TAFI >122 U/dl 17 10 1.7 1.1-2.5
Protein C inhibitor >125.5% 13 10 1.4 0.9-2.0
OTHER LABORATORY ABNORMALITIES
Homocysteine >18.5 mol/l 10 5 2.5 1.2-5.2
APC resistance for wild-type factor V <0.92 36 16 4.4 2.9-6.6
thrombophilic families, the risk of thrombosis in combina-
tion with protein C deficiency and factor V Leiden was much
higher than for relatives with only protein C deficiency.8
This gene-gene interaction results in variation within and
between families. Homozygous disease is another example
of this interaction. More commonly, a gene-environment
interaction is present in patients with thrombosis. The
synergistic effect of factor V Leiden and oral contraceptive
use was described in 1994.9 The annual absolute risk of
women who were taking oral contraceptives and were
carriers of factor V Leiden was 28.5 per 10,000 people,
whereas this risk was 5.7 per 10,000 women per year for
those with factor V Leiden without contraceptives and 3.0
per 10,000 per year for women with contraceptives without
factor V Leiden.9 An example of environment-environment
interaction is oral contraceptive use and age.9 This all shows
that the nature of thrombosis is complex. The model of
multicausal disease is not always sufficient to explain why
the clustering of these different risk factors is sufficient
to cause thrombosis in one patient but not in the other.
Refinement of this model by including the dynamic influ-
ence of age is more useful for an individual risk estimate.6
In this way we can better incorporate interaction of different
risk factors. Figure 1 shows the hypothetical situation of a
patient who is followed through life.6 This person has a
certain basic thrombosis potential, which is formed by
genetic factors (in this case factor V Leiden). Through life,
several events lead to an increased thrombosis potential.
At the age of 30 years, the combination of several risk
factors and the thrombosis potential exceeds the throm-
bosis threshold and leads to clinical disease. Since
increasing age itself is a risk factor for thrombosis, the
threshold will be reached easier at later age and less risk
factors will be needed to cause thrombosis.
Clustering and regulation
Since several procoagulant risk factors for thrombosis are
closely related in the haemostatic system, a common
genetic determinant of these coagulation factor levels
could regulate these levels additionally to environmental
determinants. A significant genetic component of coagula-
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Models of thrombosis risk.6 In each panel, the figure shows the thrombosis potential of each risk factor during an 
individual’s life and the resultant thrombosis potential
tion factors has been found in the Spanish population,10
the United Kingdom11 and the USA.12 Interestingly, six
families with a thrombotic tendency were reported in
which high levels of coagulation factors XI, IX and VIII
aggregated.13 The inheritance pattern seemed to be dominant
autosomal.13 To date, the genetic basis of high levels is
unknown. It is, however, possible that regulatory genes
outside the genes of the coagulation factors regulate 
the protein levels. These levels would then cluster in an
individual due to pleiotropic effects.
The evaluation between a potential risk factor and the
occurrence of thrombosis is becoming more difficult,
since adjustment is needed for more and more already
known thrombotic risk factors. To better estimate the role
of possible confounders and clustering of these factors, 
a priori knowledge of the interrelations of procoagulant and
anticoagulant factors is important. With the data from the
LETS, factor analysis was conducted using principal-com-
ponent analysis with varimax rotation.14 The number of
variables is reduced by constructing relatively independent
summary factors (the so-called principal components),
which explain most of the variation in the data. In large
studies where several risk factors seem to cluster, it is
important to find the smallest number of principal com-
ponents that still reflects the original data and variance.
The newly formed principal loadings can be compared
with the original variables by factor loadings, comparable
with Pearson’s correlation coefficients. When all the
measured coagulation factors of the LETS were analysed,
three relatively separate cluster patterns were found (fig-
ure 2). There was a clustering of the vitamin K dependent
factors II, VII, IX and X, together with coagulation factors
XI and XII. The second cluster consisted of factors V,
VIII, IX, and fibrinogen. The third ‘cluster’ was made up
of only one clotting factor, namely factor XIII subunit lev-
els. These results show that interrelations exist between
different coagulation factors in the haemostatic system.
Therefore, common shared genetic mechanisms may be
responsible for the clustering of these coagulation factors.
Transcription factors, such as hepatocyte nuclear factor-4,
may contribute to the first clustering pattern.15-17 Factors V
and VIII share a great part of homology and post-trans-
lational modifications and could explain the second clus-
tering.18 By using factor analysis, a better overall estimation
of the overall risk associated with coagulant factors may
become possible. The described method facilitates the
interpretation of epidemiological studies and hopefully
the determination of the thrombosis risk for individual
patients. Family studies might be helpful in unravelling
the genetic basis of these findings.
C O N S E Q U E N C E S  O F  T H R O M B O P H I L I A
Nowadays, a dozen different thrombophilia factors for
thrombosis have been elucidated. However, venous throm-
bosis is a multicausal disease in which several risk factors,
both genetic and acquired, have to occur simultaneously
to cause thrombosis.6,7 The interaction between these risk
factors is dynamic rather than static, with age as an im-
portant contributor. In this complex situation, what is the
contribution of inherited thrombophilia? And, now that we
know so many thrombophilia factors, what is the conse-
quence of thrombophilia? We will address this question by
reviewing the influence of thrombophilia on the intensity
and duration of anticoagulant therapy after a thrombo-
embolic event, the risk of recurrence of venous thrombosis
and the type of thrombosis. Thrombophilia could further
be of importance for asymptomatic individuals.
Treatment of patients with thrombophilia
The intensity of anticoagulant treatment of patients with
thrombosis who have a thrombophilia factor usually seems
identical to patients without inherited defects, although
this subject has never been thoroughly investigated.19
Even in patients with deficiencies of antithrombin, protein C
or protein S the therapeutic approach of thrombosis is
generally the same. The optimal intensity of the internatio-
nal normalised ratio (INR) is 2.0 to 3.5, and this regimen is
sufficient for preventing recurrences during therapy.20
Recently it was shown that also in subjects with the
antiphospholipid syndrome, moderate intensity anti-
coagulant therapy is adequate.21 The optimal duration of
anticoagulant therapy is uncertain, but does not seem to
be influenced by the common thrombophilia factors. The
goal of therapy is mainly to prevent recurrences. Since
factor V Leiden and the prothrombin mutation are common
in patients with thrombosis, several studies have analysed
the risk of recurrent thrombosis in association with these
prothrombotic defects. Neither of these mutations seem
Kamphuisen, et al. Thrombophilia screening.
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Figure 2
Factor loading pattern of procoagulant factors and 
fibrinogen in 466 healthy individuals14
Factor XIII A subunit












to increase the risk of recurrences, although the data are
not in complete agreement.22-27 High levels of factor VIII
and homocysteine seem to be associated with recur-
rences,28,29 but these results have to be confirmed in other
studies. Recurrent venous thrombosis might be more com-
mon in patients with a deficiency of antithrombin, pro-
tein C or protein S, but these results are based on retro-
spective data.30 Given the low prevalence of these defects,
it will be difficult to accurately determine the risk of
recurrent thrombosis. From the other known prothrom-
botic defects, the effect on recurrent thrombosis is
unknown. The combination of defects or homozygous
factor V Leiden is probably associated with an increased
risk of recurrence, although the information on patients
studied so far is low.31-36 So, apart from the antiphospholipid
syndrome,37 combined or homozygous defects, and possibly
antithrombin deficiency, the impact of thrombophilia on
the optimal duration of therapy to prevent recurrent
thrombosis is probably small.38
Clinical manifestations of thrombophilia
Thrombosis in patients with thrombophilia usually mani-
fests as deep vein thrombosis or pulmonary embolism. In
patients with thrombophilia, thrombosis can also occur at
unusual sites, such as the cerebral, visceral and axillary
veins (table 2). Superficial thrombophlebitis is more com-
mon in protein C or protein S deficiency. In rare cases
coumarin skin necrosis can occur.39 Recurrence of throm-
bosis, a family history of thrombosis and first episode of
thrombosis at young age are more common in patients
with thrombophilia. In unselected thrombosis patients
with a prothrombotic defect, such as factor V Leiden or
prothrombin mutation, the difference with thrombosis
patients without a defect is less clear.8
prospectively followed asymptomatic carriers of the factor V
Leiden mutation.40 In 470 individuals, the annual incidence
of venous thrombosis was 0.58%, which does not justify
routine screening of family members. Also in risk situ-
ations, such as pregnancy or oral contraceptive use, the
rate of thrombosis was low.40 In pregnant asymptomatic
women heterozygous for factor V Leiden or the pro-
thrombin mutation, absolute risk of thrombosis is less
than 3%,41,42 whereas a deficiency of antithrombin, protein C
or protein S leads to a risk of 4.1%.43 Taken together, the
risk of thrombosis in asymptomatic carriers of thrombo-
philia defects seems low and does not justify screening.
The optimal strategy of thrombosis prophylaxis of asymp-
tomatic carriers is probably not different from patients
without heritable thrombophilia, but this subject remains
controversial as long as there are no trials comparing pro-
longed prophylaxis with standard prophylaxis in high-risk
situations or prophylaxis vs placebo during pregnancy.44
I M P L I C A T I O N S  O F  T H R O M B O P H I L I A
S C R E E N I N G
Testing for thrombophilia is subject to an intense pro-con
debate.45,46 Clinicians who perform thrombophilia screening
usually argue that a better understanding of the patho-
genesis of thrombosis is important for both the treating
physician and for the patient. Family members of the
proband with a prothrombotic defect can also be screened,
in order to tailor prophylactic treatment during high-risk
situations.47 Others argue against screening since screening
is not cost-effective and leads to anxiety among asymp-
tomatic carriers or false reassurance in those without the
defect.46 Apart from the discussion whether screening
should be performed, it is important how to interpret the
results of studies for thrombophilia. What are the impli-
cations for an individual patient, for the family members,
the treating physician, researcher or even the society?
Influence of patient selection on the association of
thrombophilia and thrombosis
The strength of an association between an inherited
coagulation defect and venous thrombosis can be influ-
enced by the type of study and the selection of thrombosis
patients and controls.7 In cohort (follow-up) studies, quanti-
tative estimates (i.e. absolute risks) can be obtained. In
case-control studies one can estimate relative risks (as an
odds ratio) by comparing thrombosis patients with
healthy individuals. This figure indicates how much higher
the thrombosis risk is in the presence of a certain risk
factor than in the absence of that factor. In unselected
cases from population-based studies, relative risks can be
applied to all individuals with that particular risk factor,
provided cases are well selected. Population-based case-
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Table 2
Clinical manifestations of thrombophilia
Venous thrombosis at unusual site: mesenteric, pelvic, cerebral 
sinuses, portal, axillary
Family history of venous thromboembolism
Onset of thrombosis at young age
Recurrent episodes of venous thromboembolism




Thrombophilia in asymptomatic patients
In women with the factor V Leiden or prothrombin muta-
tion, oral contraceptive use, hormone replacement therapy
and pregnancy further increase the risk of thrombosis,
but the absolute risk seems to be low. Middeldorp et al.
control studies can be used to calculate the attributable
risk, i.e., the proportion of all thrombotic events that would
have been prevented by removing the risk factor. Family
studies often consist of subjects that were selected because
of a conspicuously high frequency of thrombosis. In these
studies, the occurrence of thrombosis is compared
between family members with and without the risk factor.
These studies are ideal for studying the type of inheritance
of a certain risk factor and to qualitatively estimate the
thrombosis risks. These thrombophilia families usually have
more than one thrombophilic defect and results cannot be
extrapolated to the general population. The influence of
selection is well reflected in the age of onset of thrombosis
that clearly differs between individuals from thrombophilia
families and unselected thrombosis patients.48 Finally,
other aspects such as an objective diagnosis of thrombosis
and prospective vs retrospective studies also influence the
estimates of risk.
Importance of a risk factor for thrombosis
With so many new risk factors emerging, the question is
what impact they have in daily clinical practice. In other
words, how can the results from research be translated into
practical clinical guidelines? First of all, we must make
sure that the new risk factor is independent and clinically
relevant. This requires full adjustment for potential con-
founders, such as age, sex, body mass index, and other
coagulation factors. This does not apply for genetic risk
factors, since these are by definition unconfounded.
It is important to appreciate and interpret the differences
between absolute and relative risks. The relative risks that
have been calculated from case-control studies are mainly
important to the researcher, whereas absolute risk estimates
(the probability to develop thrombosis and the possibility
to lower this probability) is relevant to the individual
patient and his physician.49 Population-attributable risk
estimates are also important for the population and can
influence decision-making. Asymptomatic females with
deficiencies of antithrombin, protein C, or protein S have
an eightfold increased relative risk of thrombosis during
pregnancy.30 The absolute risk is 4.1% (7 in 169 preg-
nancies). So, these deficiencies have a high magnitude of
risk, but because of the low prevalence, account for only a
small percentage of the overall thrombosis risk. Likewise,
oral contraceptives and hormone replacement therapy
both increase the risk of the thrombosis approximately
fourfold. Since the baseline risk of thrombotic disease is
nearly tenfold higher in the older HRT users, their basic
risk of thrombosis is greater than in women who are on oral
contraceptives.49 Hypertension is a moderate risk factor
for congestive heart failure, but accounts for nearly half
of the cases of heart failure in a population.50 So, in general,
common risk factors usually have moderate relative risks,
but are important at population level when its prevalence
is high. Strong risk factors are generally less important
for healthy individuals.
If we consider thrombophilia screening for risk factors, the
measurement must be reliable (low coefficient of variation)
and reflect a true representation of the risk factor. For
prothrombotic mutations, such as factor V Leiden and
prothrombin mutation, this is generally not a problem.
Most coagulation factors, such as factor VIII, however, have
a large intra-individual and inter-assay variation, as reflected
in the decision to use the factor VIII measurements of three
different plasma samples to calculate the probability of
carriership of haemophilia A. Further, there is the important
question how we should interpret the result of a measure-
ment in terms of risk of a first thrombotic event and risk
of recurrences. Most risk factors have wide ranges of values
with large overlap between individuals with and without
thrombosis. These risk factors typically increase with
increasing levels, without a clear threshold. So, artificial
cut-off values which were used in clinical research are
being used now for decision-making in individual
patients. It is unknown whether these cut-off values are
practical and reliable. We do not know the sensitivity or
specificity of most risk factors for predicting future occur-
rences of thrombosis. Factor VIII levels can easily rise
above the cut-off value of 150 IU/dl due to acute phase
reactions, such as a thrombotic event. This transient rise
may cause a mislabelling of a person with venous throm-
bosis who normally has a low factor VIII level.51 Since
factor VIII levels may be associated with the risk of 
recurrences,28 a treating physician might decide to 
prolong anticoagulant therapy on the basis of a single
measurement. This shows that the results from research
cannot simply be extrapolated to patient care and can even
lead to wrong decisions (primum non nocere).
I M P L I C A T I O N S  O F  T H R O M B O P H I L I A
S C R E E N I N G  F O R  T H E  I N D I V I D U A L
P A T I E N T
As already stated, relative risk has no value in the clinic,
and only knowledge of the absolute risk of developing
thrombosis may have relevance for the individual patient,
and then still only if this leads to the possibility of preven-
tion. This would imply that for each patient at risk of a first
episode of thrombosis or for a recurrent event, an indivi-
dualised risk profile should be available with age, sex,
current risk factors and the possibility of future risk factors,
such as trauma, surgery and pregnancy, while for each
factor its strength should be known, as well as its inter-
action with the other factors. This scenario is still far away.
It is not even feasible to readily identify patients with
thrombophilia unless all thrombosis patients are screened,
since half of the first thrombotic events in patients with
Kamphuisen, et al. Thrombophilia screening.
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thrombophilia are not idiopathic and occur in high-risk
situations. Practical recommendations have been suggested
to guide screening strategies in patients with thrombosis,
in which patients are divided in ‘strongly’ and ‘weakly’
thrombophilic.19 The ‘strongly’ thrombophilic patients
include patients with age at onset <50 years, patients with
recurrent thrombosis, or first-degree family members with
a thrombotic event before 50 years of age. All other patients
are ‘weakly’ thrombophilic and should be screened for the
common defects such as factor V Leiden and prothrombin
mutation, while the former group should also be tested for
the more rare defects such as deficiencies of protein C,
protein S and antithrombin. This strategy optimises the
likelihood of finding a prothrombotic abnormality, but
does not necessarily benefit the patient. With the current
knowledge it is questionable whether the presence of a
risk factor leads to any difference in clinical management,
and therefore screening does not seem helpful. The most
compelling question is whether, based on laboratory tests,
we can predict the risk of recurrence and, while the various
studies are not in complete agreement, it may well be that
the risk of recurrence is not increased in the presence of
prothrombotic defects. In that case it makes more sense
to base clinical strategy on clinical history, i.e., the severity
of the event or the age of the patient, than on laboratory
tests. The next question concerns asymptomatic relatives:
is it useful to screen asymptomatic individuals from a
family with hereditary thrombophilia, for instance women
who intend to become pregnant or want to start oral
contraceptives? Again, the literature offers little assistance,
except that in most cases the risk of thrombosis appears
to be low. Women from families with a strong history of
thrombosis may consider not using oral contraceptives.
C O N C L U S I O N
The last decade revealed several new risk factors that con-
tribute to a better understanding of the pathogenesis of
venous thrombosis. Well-designed large population-based
case-control studies were a prerequisite for establishing new
risk factors, such as factor V Leiden, prothrombin 20210A
mutation, procoagulant factors, as factor VIII, IX, and XI,
and antifibrinolytic factors, such as TAFI. Since many
individuals with a thrombophilic factor are asymptomatic,
a single defect is seldom sufficient to cause thrombosis.
Thrombosis is thus a multicausal disease, in which genetic
and environmental factors interact dynamically. The com-
mon risk factors with a high prevalence in the general
population make a major contribution to the overall risk
of thrombosis. These risk factors are likely to occur
simultaneously in an individual with thrombosis. When
these clusters of risk factors can be identified, preventive
measures can be installed, mainly for those individuals
with a genetic predisposition. This can only be assessed
adequately through sufficient knowledge of important
risk factors for thrombosis, their effect and interaction
with other genetic and environmental factors, and the
beneficial effect of intervention. Until that time, screening
for thrombophilia will remain a matter of debate.
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